lung health and sleep enhancement center
Clinical research trials are a vital part of the development of new
medications, treatment options, and medical technologies.
Participation in a clinical trial encourages patients to take an active role
in their health care and is an invaluable resource in their treatment.
LHSEC (Lung Health and Sleep Enhancement Center) is a comprehensive
division of Pulmonary Associates, dedicated to the advancement of pulmonary
medicine in all it's aspects. Since 1994, LHSEC has participated in
numerous trials and continues to do so.
Currently, we are conducting research in the following fields:
- Asthma
- COPD
- Pulmonary Arterial Hypertension
For more information on specific studies we are involved in, see below.
Additional updates will be posted when made available.
COMPASS 3 is an open-label, prospective, phase 4, multicenter study
evaluating the effectiveness of bosentan, alone or in combination with
sildenafil to improve a patient's ability to exercise.
Another purpose of the study is to explore how the structure of the heart
changes when taking bosentan alone or in combination with sildenafil.
The primary objective of this 100 subject trial is to determine the
percentage of patients that achieve a target 6-MWT distance using a bosentan-based,
stepped approach to therapy.
Eligible patients must be at least 18 years of age and be naive to treatment
with advanced PAH (Pulmonary Arterial Hypertension) therapies.
Contact the following staff for more information on this trial:
Gerald M. O'Brien, MD - Primary Investigator
302-368-5515
Julie M. Adams, RN BC CCRC - Study Coordinator
302-368-5515 ext. 104
